Pharma Industry
Industry: Email Alert RSS FeedGENE THERAPY: Vector Transfers Genes to Bone Marrow - Cell Genesys, Inc's lentivirus vectors - Company Business and Marketing
Applied Genetics News, April, 1999
Cell Genesys, Inc. (342 Lakeside Dr., Foster City, CA 94404; Tel: 650/425-4400, Fax: 650/358-0803), in collaboration with scientists from Children's Hospital Los Angeles and the Markey Cancer Center of the University of Kentucky, has demonstrated efficient long term gene delivery to bone marrow stem cells using the company's lentiviral gene delivery system.
Most RecentPharma Articles
- GlaxoSmithKline Target of Claims That Denture Cream Causes Neurological Problems
- UPDATED: Suicide Follows Stabbing Linked to Pfizer Layoffs
- Bayer in "Jaw Dropping" Fight Over Its Coal Bill
- Sanofi Plans Layoffs on Dec. 30; Management Says "Happy Thanksgiving!"
- J&J CEO Rubs Pfizer's Face in Disastrous Consumer Products Sale of '06
- More »
The vector successfully transferred a marker gene to 29% of targeted cells. Unlike a previously used retroviral vector, the lentivirus system was able to deliver genes to non-dividing cells. Stable expression of the introduced gene was observed over the 15- week duration of the study. The data were reported in the March 16, 1999 issue of the Proceedings of the National Academy of Sciences. "Successful gene transfer with lentiviral vectors signifies an important step forward in stem cell gene therapy research and overcomes a major limitation of other viral and non- viral gene delivery systems," says Mitchell H. Finer, vice president of research at Cell Genesys. Effective genetic modification of bone marrow stem cells could be the basis of immune-based strategies for the treatment of AIDS, cancer, and other diseases. Progress in stem cell gene therapy research has been hampered by the inability of previous gene delivery systems to deliver genes to non-dividing stem cells at levels high enough to have therapeutic benefit. The lentivirus vectors employed by Cell Genesys were derived from HIV. Company scientists have enhanced the safety profile of the vectors by using only three of the nine genes present in the parent virus. The genes removed were involved with viral replication and pathogenesis. Removal of these genes did not decrease the gene transfer efficiency of the vector. The newest engineered vectors have a built-in safety mechanism that eliminates the possibility of recombination with infectious virus, reports Cell Genesys. These third generation vectors are believed to have potential in human gene therapy.
- How to choose the right insurance carrier for your business
- Real Estate: Prepare your properties to weather what lies ahead
- Technology: Be prepared if part of your global supply chain goes missing
Most Recent Health Articles
Most Recent Health Publications
Most Popular Health Articles
- 50 home remedies that work: these safe, fast, and effective fixes will relieve what ails you - Cover Story
- Detox in 7 days: a detoux diet can help you shed up to 10 pounds and leave you feeling terrific. Our weeklong plan shows you how to lose the weight and keep it off - Cover story
- Treat sinusitis naturally: breath easy and relieve sinus pressure with these remedies - Quick Fixes and Long-Term Solutions
- All about nightshades: explore the hidden hazards of your favorite food with macrobiotic nutritionist Lino Stanchich
- La anemia falciforme - causas y tratamiento



